Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells past the immune system

After leading one of the early pioneers in customized cancer therapies using patient cells for CAR-T, the founding execs at Sana Biotechnology are now nailing down the IP for a new generation of off-the-shelf cell therapies that they believe can have built-in protection against an immune response.